PDF(Pubmed)
Abstract：
UNASSIGNED: Metastatic breast cancers (MBC) with no expression of human epidermal growth factor receptor-2 (HER2) are recently classified into two groups; HER2-zero [HER2-immunohistochemistry (IHC) score of 0 (IHC-0)] and HER2-low, defined as those with IHC score of 1+ or 2+ with negative in situ hybridization (ISH) assay. We investigate differences in treatment outcomes between both groups treated with endocrine therapy (ET) and the CDK4/6 inhibitor ribociclib.
UNASSIGNED: Data were retrospectively collected for patients with HR-positive+/HER2-negative MBC who received ribociclib with an aromatase inhibitor (AI) or fulvestrant and were divided into two groups: HER2-zero and HER2-low.
UNASSIGNED: A total of 257 patients, median age 48 (22-87) years, all with MBC who were treated with ET and ribociclib were enrolled. One hundred and thirty-seven (53.3%) patients had de novo MBC, and majority (n = 162, 63.0%) received ribociclib as a first-line therapy. In total, 114 (44.4%) patients had HER2-zero (IHC-0), while 143 (55.6%) others had HER2-low disease. The overall response rate (ORR) was 52.0% for the HER2-zero group compared to 39.4% for the HER2-low group, p = 0.005. The median PFS was 22.2 (95% confidence interval [CI], 19.4-NR) months for HER2-zero versus 17.3 (95% CI, 14.1-20.6) months for HER2-low, P = 0.0039. In multivariable analysis, HER2-low expression remained significant determinant of inferior PFS after adjusting for other factors, including the site of metastasis, prior chemotherapy, and the line of treatment.
UNASSIGNED: In patients with MBC treated with ET and ribociclib, level of HER2 negativity may affect treatment outcomes; patients with HER2-zero had better response rate and PFS compared to those with HER2-low disease. These findings, if confirmed in larger studies, may help oncologists select patients with HER2-low for better treatment options.
UNASSIGNED: Data were retrospectively collected for patients with HR-positive+/HER2-negative MBC who received ribociclib with an aromatase inhibitor (AI) or fulvestrant and were divided into two groups: HER2-zero and HER2-low.
UNASSIGNED: A total of 257 patients, median age 48 (22-87) years, all with MBC who were treated with ET and ribociclib were enrolled. One hundred and thirty-seven (53.3%) patients had de novo MBC, and majority (n = 162, 63.0%) received ribociclib as a first-line therapy. In total, 114 (44.4%) patients had HER2-zero (IHC-0), while 143 (55.6%) others had HER2-low disease. The overall response rate (ORR) was 52.0% for the HER2-zero group compared to 39.4% for the HER2-low group, p = 0.005. The median PFS was 22.2 (95% confidence interval [CI], 19.4-NR) months for HER2-zero versus 17.3 (95% CI, 14.1-20.6) months for HER2-low, P = 0.0039. In multivariable analysis, HER2-low expression remained significant determinant of inferior PFS after adjusting for other factors, including the site of metastasis, prior chemotherapy, and the line of treatment.
UNASSIGNED: In patients with MBC treated with ET and ribociclib, level of HER2 negativity may affect treatment outcomes; patients with HER2-zero had better response rate and PFS compared to those with HER2-low disease. These findings, if confirmed in larger studies, may help oncologists select patients with HER2-low for better treatment options.
摘要：
■不表达人表皮生长因子受体2（HER2）的转移性乳腺癌（MBC）最近被分为两组；HER2-零[HER2-免疫组织化学（IHC）评分为0（IHC-0）]和HER2-低，定义为IHC评分为1或2，原位杂交（ISH）阴性的那些。我们研究了接受内分泌治疗（ET）和CDK4/6抑制剂ribociclib治疗的两组之间治疗结果的差异。
■回顾性收集HR阳性+/HER2阴性MBC患者的数据，这些患者接受瑞博西尼联合芳香化酶抑制剂(AI)或氟维司群，并分为两组：HER2-零和HER2-低。
■总共257名患者，中位年龄48（22-87）岁，纳入所有接受ET和瑞博西尼治疗的MBC患者.一百三十七（53.3％）患者有从头MBC，大多数（n=162，63.0％）接受了瑞博西尼作为一线治疗。总的来说,114例（44.4%）患者有HER2-零（IHC-0），而其他143例（55.6%）患有低HER2疾病。HER2零组的总有效率（ORR）为52.0％，而HER2低组为39.4％，p=0.005。中位PFS为22.2(95%置信区间[CI]，19.4-NR)个月为HER2-零，而17.3(95%CI，14.1-20.6)个月为低HER2，P=0.0039。在多变量分析中，在调整其他因素后，HER2低表达仍然是低PFS的重要决定因素，包括转移部位,先前的化疗，和治疗路线。
■在接受ET和瑞博西尼治疗的MBC患者中，HER2阴性水平可能会影响治疗结局;与HER2-0患者相比,HER2-0患者的缓解率和PFS更好.这些发现,如果在更大的研究中得到证实，可以帮助肿瘤学家选择低HER2患者以获得更好的治疗方案.
■回顾性收集HR阳性+/HER2阴性MBC患者的数据，这些患者接受瑞博西尼联合芳香化酶抑制剂(AI)或氟维司群，并分为两组：HER2-零和HER2-低。
■总共257名患者，中位年龄48（22-87）岁，纳入所有接受ET和瑞博西尼治疗的MBC患者.一百三十七（53.3％）患者有从头MBC，大多数（n=162，63.0％）接受了瑞博西尼作为一线治疗。总的来说,114例（44.4%）患者有HER2-零（IHC-0），而其他143例（55.6%）患有低HER2疾病。HER2零组的总有效率（ORR）为52.0％，而HER2低组为39.4％，p=0.005。中位PFS为22.2(95%置信区间[CI]，19.4-NR)个月为HER2-零，而17.3(95%CI，14.1-20.6)个月为低HER2，P=0.0039。在多变量分析中，在调整其他因素后，HER2低表达仍然是低PFS的重要决定因素，包括转移部位,先前的化疗，和治疗路线。
■在接受ET和瑞博西尼治疗的MBC患者中，HER2阴性水平可能会影响治疗结局;与HER2-0患者相比,HER2-0患者的缓解率和PFS更好.这些发现,如果在更大的研究中得到证实，可以帮助肿瘤学家选择低HER2患者以获得更好的治疗方案.
